In the latest episode of the Denatured podcast, Jennifer C. Smith-Parker, Director of Insights at BioSpace, hosts a discussion on financing strategies in the biotech sector. The conversation features Ram May-Ron, managing partner at FreeMind Group, and Ravi Kiron, managing director at Biopharma Strategy Advisors.
The episode examines how biotech companies can combine nondilutive funding sources such as grants with investments from family offices to address challenges in drug development. The guests share their perspectives on overcoming what is commonly known as the "valley of death" in drug development—a period where many projects fail due to lack of funding.
The discussion covers ways to tailor investment approaches that leverage both traditional grant funding and capital from family offices. According to the participants, this combination can help biotech firms bridge critical gaps during early-stage research and development.
"The views expressed in this discussion by guests are their own and do not represent those of their organizations," according to a disclaimer included in the episode.
The podcast is available on several platforms including Spotify, Apple Podcasts, Amazon Music, and iHeart.
